Muñoz-Ortiz Juliana, Sierra-Cote Maria Camila, Zapata-Bravo Estefanía, Valenzuela-Vallejo Laura, Marin-Noriega Maria Alejandra, Uribe-Reina Pilar, Terreros-Dorado Juan Pablo, Gómez-Suarez Marcela, Arteaga-Rivera Karla, de-la-Torre Alejandra
Escuela Barraquer Research Group, Escuela Superior de Oftalmología del Instituto Barraquer de América, Avenida Calle 100 No. 18A - 51, Bogotá, Colombia.
Research Group in Neurosciences NeURos, Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Carrera 24 # 63C 69, Bogotá, Colombia.
Syst Rev. 2020 Sep 1;9(1):201. doi: 10.1186/s13643-020-01459-7.
Thyroid eye disease is an autoimmune disorder of the orbital retrobulbar tissue commonly associated with dysthyroid status. The most frequent condition is hyperthyroidism, although it is also present in hypothyroid and euthyroid patients. The prevalence of thyroid conditions in patients with thyroid eye disease had been previously evaluated; however, there is no consensus on a global prevalence. The study aims to estimate the prevalence of hyperthyroidism, hypothyroidism, and euthyroidism in patients with TED, through a systematic review of literature.
We conducted a systematic review of the literature following the PRISMA guidelines, in MEDLINE, COCHRANE, EMBASE, Science Direct, and LILACS databases. Inclusion criteria were primary studies of patients with a diagnosis of thyroid eye disease made by an ophthalmologist or with diagnosis criteria, with measurement of thyroid function (TSH, T3, and free T4), and diagnosis of the primary thyroid condition. A quality assessment was made through the Joanna Briggs Institute Quality tools. Finally, we extracted relevant details about the design, the results, and the prevalence of thyroid disorders in thyroid eye disease.
The initial search revealed 916 studies, of which finally thirteen met inclusion criteria. Six studies were performed in Europe (Germany, Wales, and Spain), five in Asia (Iran, South Korea, Japan, and Singapore), one in North America (USA), and one in Africa (Ghana). The global prevalence, in patients of thyroid eye disease, was 10.36% for hypothyroidism, 7.9% for euthyroidism, and 86.2% for hyperthyroidism.
Professionals should be aware that thyroid eye disease can be present in patients with a normal thyroid function. The assessment for these patients is based on orbital images; serum TSH, T3, and free T4; antibody levels as thyrotropin receptor antibodies; and thyroperoxidase levels. Additionally, we want to encourage research in this field in other regions of the world such as Latin America.
PROSPERO ID CRD42020107167.
甲状腺眼病是一种眼眶球后组织的自身免疫性疾病，通常与甲状腺功能异常有关。最常见的情况是甲状腺功能亢进，不过甲状腺功能减退和甲状腺功能正常的患者也会出现。此前已对甲状腺眼病患者的甲状腺疾病患病率进行过评估；然而，全球患病率尚无定论。本研究旨在通过系统的文献综述，估计甲状腺眼病患者中甲状腺功能亢进、减退和正常的患病率。
我们按照PRISMA指南，在MEDLINE、COCHRANE、EMBASE、Science Direct和LILACS数据库中对文献进行了系统综述。纳入标准为眼科医生诊断为甲状腺眼病的患者的原发性研究，或具有诊断标准、甲状腺功能（促甲状腺激素、T3和游离T4）测量以及原发性甲状腺疾病诊断的研究。通过乔安娜·布里格斯研究所质量工具进行质量评估。最后，我们提取了有关甲状腺眼病中甲状腺疾病的设计、结果和患病率的相关详细信息。
初步检索发现916项研究，最终13项符合纳入标准。6项研究在欧洲（德国、威尔士和西班牙）进行，5项在亚洲（伊朗、韩国、日本和新加坡），1项在北美（美国），1项在非洲（加纳）。甲状腺眼病患者中，甲状腺功能减退的全球患病率为10.36%，甲状腺功能正常为7.9%，甲状腺功能亢进为86.2%。
专业人员应意识到甲状腺功能正常的患者也可能患有甲状腺眼病。对这些患者的评估基于眼眶图像、血清促甲状腺激素、T3和游离T4、促甲状腺激素受体抗体等抗体水平以及甲状腺过氧化物酶水平。此外，我们鼓励在世界其他地区如拉丁美洲开展该领域的研究。
PROSPERO编号CRD42020107167。
Zotero 插件
